The cerebrolysin group showed statistically significant improvements across multiple measures: the Sandoz Clinical Assessment Geriatric scale, self-assessment scores, cognitive performance measures, and concentration testing for elderly patients
Differential Diagnosis Conditions that may mimic CSVD include: Alzheimers disease Multiple sclerosis Normal pressure hydrocephalus Vasculitis Leukodystrophies Neurodegenerative movement disorders Mixed pathology is common, particularly coexistence of CSVD and Alzheimers disease
While the CXXC5 mechanism appears conserved between mice and humans (elevated CXXC5 is found in human bald scalps), the functional response to PTD-DBM treatment in humans may differ in magnitude, timeline, or both
0% placebo) Headache (reported in at least 10% with bremelanotide) Local injection reactions: pain, redness, swelling Dizziness or lightheadedness Temporary increases in blood pressure Mild-to-moderate fatigue or malaise Rare but serious events include pronounced hypertensive episodes, severe allergic reactions, syncope, and less well-documented cardiac events in people with underlying heart disease